Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Surrozen Inc.
Headquarters: South San Francisco, CA, United States of America
Website: https://surrozen.com/
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: Craig C. Parker, MBA
Number Of Employees: 42
Enterprise Value: $-13,694,800
PE Ratio: -0.62
Exchange/Ticker 1: NASDAQ:SRZN
Exchange/Ticker 2: N/A
Latest Market Cap: $34,122,900
BioCentury | Apr 6, 2024
Finance
Public equity report: Contineum’s NASDAQ listing, Oruka’s financing-merger combo
Plus: Surrozen and Sutro raise cash, and Redx proposes to delist from London’s AIM
BioCentury | Mar 7, 2023
Product Development
Eyebiotech targets Wnt pathway with first retinal program
Biotech discloses details one year after $65M series A round
BioCentury | Oct 7, 2022
Deals
Oct. 6 Quick Takes: BioMarin restructuring to cut 120 employees
Plus Merck KGaA opening up to larger M&A, Sanofi, Provention to co-promote diabetes treatment and updates from Annovis, Aldeyra and more
BioCentury | Oct 22, 2021
Management Tracks
New board chairman at Dynavax
Plus: Arcturus, BioDelivery, Landmark Bio, Vitrolife, Novome and more
BioCentury | Sep 2, 2021
Management Tracks
Novo Ventures’ Lüneborg joins Forbion
Nallicheri ascends to CEO at EQRx, plus: Hummingbird’s new CFO, Acadia, Pillar, Ribon and more
BioCentury | Jun 5, 2021
Translation in Brief
Wave provides POC for RNA editing platform; plus Surrozen, Pinteon and Minoryx
BioCentury’s roundup of translational news
BioCentury | Apr 20, 2021
Product Development
Patient groups’ pandemic pain; plus voters’ rights and synthetic lethality: a BioCentury podcast
The pandemic has hurt patient groups that have heavily relied on in-person events for fund-raising and patient outreach. On the latest BioCentury This Week, BioCentury’s editors discuss the
BioCentury | Apr 17, 2021
Deals
April 16 Quick Takes: AZ’s $39B Alexion deal clears FTC hurdle; plus Biosplice, C2i, Relay, Surrozen and more
The FTC has cleared the $39 billion takeout of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by AstraZeneca plc (LSE:AZN; NASDAQ:AZN), clearing a hurdle for the pharma at a time when biopharma
BioCentury | Apr 14, 2021
Finance
Tango & Cash: the latest in string of biotech SPAC mergers: Data Byte
Tango, Surrozen bring SPACs this year to 22
BioCentury | Nov 3, 2020
Management Tracks
Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more
Gene therapy developer Freeline Therapeutics Holdings plc (NASDAQ:FRLN) hired Mark Baldry as chief commercial officer. He previously held the same role at Wave Life Sciences Ltd. (NASDAQ:WVE).
Items per page:
1 - 10 of 21